We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Shares of Capricor Therapeutics (CAPR) are trading up by about 13% on Thursday noon after the company announced ...

Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Edward T ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with ...

AlphaQuest LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) during the fourth quarter, ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

FDA accepts Capricor's Biologics License Application for priority review, advancing deramiocel for DMD cardiomyopathy.

SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Wednesday reported a loss of $7.1 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

The biotechnology company posted adjusted earnings per share of -$0.16 for Q4, beating analyst estimates by $0.01. Revenue came in at $11.13 million, significantly above the consensus forecast of ...

Capricor Therapeutics (NASDAQ:CAPR) is scheduled to announce Q4 earnings results on Wednesday, March 19th, after market close. The consensus EPS Estimate is -$0.09 (-350.0% Y/Y) and the consensus ...